Disparities in OUD treatment: Buprenorphine vs. naltrexone
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
(Part 1) When clients see real-world data (RWD) in HealthVerity Marketplace, it may appear...
Electronic Health Records (EHR): What they are and how to use them in real-world data Electronic...
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and...
HealthVerity recently introduced HealthVerity Notes, our newest product designed to unlock the...
AI-driven mortality models are supposed to provide accurate, data-backed insights into patient...
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1...
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically, w...